A new Ni(II) monomer [Ni(L)2(NCS)2] has been synthesized using a Schiff base ligand (HL = 2-[(3-Dimethylaminopropylimino)-methyl]-phenol) and characterized by X-ray crystallography, FT-IR, and UV-Vis. spectroscopic techniques. Single crystal X-ray analysis reveals that it is a mononuclear bis-ligand complex with two axially coordinated NCS– co-ligands. The zwitterionic Schiff base ligands are chelated to the central Ni atom in trans fashion through imine N atoms and phenoxido O atoms with N–Ni–O chelating angles of 87.94(4)°. The octahedral coordination of Ni(II) is completed by two axial thiocyanate anions bonded through their nitrogen end with Ni-N bond distances of 2.103(3)Å. For an in vitro antileishmanial study, the compound was screened against L. donovani parasites, and it was found that the compound has moderate anti-promastigote activity with an IC50 of 70.04 ± 1 µg/mL when compared to the reference drug Miltefosine. It reasonably deescalated intracellular parasites from the leishmania-infected macrophages with appreciably low toxicity towards RAW 264.7 cells.CC50 and SI index have also been calculated for the test compound and the reference drug. Molecular docking analysis has been executed to find information regarding the interactions with the target protein PEX5. The nature and the strength of the intermolecular interactions have evaluated by means of a molecular electrostatic potential map. Density functional theory (DFT) analysis predicted the compound’s optimized geometry and HOMO-LUMO band gap. DFT computation and docking studies are in good agreement with the most relevant biological findings. This compound can be contemplated as a leading scaffold having the prospect for further molecular modifications before considering it as a potential antileishmanial candidate.



